What does PD-L1 positive or negative mean?

被引:265
作者
Ribas, Antoni [1 ,2 ]
Hu-Lieskovan, Siwen [1 ,2 ]
机构
[1] Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, JCCC, Los Angeles, CA 90095 USA
基金
美国国家卫生研究院;
关键词
CELL LUNG-CANCER; ADAPTIVE IMMUNE RESISTANCE; ADVANCED MELANOMA; UNTREATED MELANOMA; CLINICAL ACTIVITY; HODGKIN LYMPHOMA; OPEN-LABEL; EXPRESSION; BLOCKADE; NIVOLUMAB;
D O I
10.1084/jem.20161462
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Expression of the programmed death-1 (PD-1) ligand 1 (PD-L1) is used to select patients and analyze responses to anti-PD-1/L1 antibodies. The expression of PD-L1 is regulated in different ways, which leads to a different significance of its presence or absence. PD-L1 positivity may be a result of genetic events leading to constitutive PD-L1 expression on cancer cells or inducible PD-L1 expression on cancer cells and noncancer cells in response to a T cell infiltrate. A tumor may be PD-L1 negative because it has no T cell infiltrate, which may be reversed with an immune response. Finally, a tumor that is unable to express PD-L1 because of a genetic event will always be negative for PD-L1 on cancer cells.
引用
收藏
页码:2835 / 2840
页数:6
相关论文
共 47 条
  • [1] Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
    Akbay, Esra A.
    Koyama, Shohei
    Carretero, Julian
    Altabef, Abigail
    Tchaicha, Jeremy H.
    Christensen, Camilla L.
    Mikse, Oliver R.
    Cherniack, Andrew D.
    Beauchamp, Ellen M.
    Pugh, Trevor J.
    Wilkerson, Matthew D.
    Fecci, Peter E.
    Butaney, Mohit
    Reibel, Jacob B.
    Soucheray, Margaret
    Cohoon, Travis J.
    Janne, Pasi A.
    Meyerson, Matthew
    Hayes, D. Neil
    Shapiro, Geoffrey I.
    Shimamura, Takeshi
    Sholl, Lynette M.
    Rodig, Scott J.
    Freeman, Gordon J.
    Hammerman, Peter S.
    Dranoff, Glenn
    Wong, Kwok-Kin
    [J]. CANCER DISCOVERY, 2013, 3 (12) : 1355 - 1363
  • [2] PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
    Ansell, Stephen M.
    Lesokhin, Alexander M.
    Borrello, Ivan
    Halwani, Ahmad
    Scott, Emma C.
    Gutierrez, Martin
    Schuster, Stephen J.
    Millenson, Michael M.
    Cattry, Deepika
    Freeman, Gordon J.
    Rodig, Scott J.
    Chapuy, Bjoern
    Ligon, Azra H.
    Zhu, Lili
    Grosso, Joseph F.
    Kim, Su Young
    Timmerman, John M.
    Shipp, Margaret A.
    Armand, Philippe
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) : 311 - 319
  • [3] PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells
    Blank, C
    Brown, I
    Peterson, AC
    Spiotto, M
    Iwai, Y
    Honjo, T
    Gajewski, TF
    [J]. CANCER RESEARCH, 2004, 64 (03) : 1140 - 1145
  • [4] MYC regulates the antitumor immune response through CD47 and PD-L1
    Casey, Stephanie C.
    Tong, Ling
    Li, Yulin
    Do, Rachel
    Walz, Susanne
    Fitzgerald, Kelly N.
    Gouw, Arvin M.
    Baylot, Virginie
    Guetgemann, Ines
    Eilers, Martin
    Felsher, Dean W.
    [J]. SCIENCE, 2016, 352 (6282) : 227 - 231
  • [5] Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients
    Cha, Edward
    Klinger, Mark
    Hou, Yafei
    Cummings, Craig
    Ribas, Antoni
    Faham, Malek
    Fong, Lawrence
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (238)
  • [6] Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity
    Dorand, R. Dixon
    Nthale, Joseph
    Myers, Jay T.
    Barkauskas, Deborah S.
    Avril, Stefanie
    Chirieleison, Steven M.
    Pareek, Tej K.
    Abbott, Derek W.
    Stearns, Duncan S.
    Letterio, John J.
    Huang, Alex Y.
    Petrosiute, Agne
    [J]. SCIENCE, 2016, 353 (6297) : 399 - 403
  • [7] IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression
    Dunn, GP
    Sheehan, KCF
    Old, LJ
    Schreiber, RD
    [J]. CANCER RESEARCH, 2005, 65 (08) : 3447 - 3453
  • [8] Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
    Garon, Edward B.
    Rizvi, Naiyer A.
    Hui, Rina
    Leighl, Natasha
    Balmanoukian, Ani S.
    Eder, Joseph Paul
    Patnaik, Amita
    Aggarwal, Charu
    Gubens, Matthew
    Horn, Leora
    Carcereny, Enric
    Ahn, Myung-Ju
    Felip, Enriqueta
    Lee, Jong-Seok
    Hellmann, Matthew D.
    Hamid, Omid
    Goldman, Jonathan W.
    Soria, Jean-Charles
    Dolled-Filhart, Marisa
    Rutledge, Ruth Z.
    Zhang, Jin
    Lunceford, Jared K.
    Rangwala, Reshma
    Lubiniecki, Gregory M.
    Roach, Charlotte
    Emancipator, Kenneth
    Gandhi, Leena
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (21) : 2018 - 2028
  • [9] Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
    Green, Michael R.
    Monti, Stefano
    Rodig, Scott J.
    Juszczynski, Przemyslaw
    Currie, Treeve
    O'Donnell, Evan
    Chapuy, Bjoern
    Takeyama, Kunihiko
    Neuberg, Donna
    Golub, Todd R.
    Kutok, Jeffery L.
    Shipp, Margaret A.
    [J]. BLOOD, 2010, 116 (17) : 3268 - 3277
  • [10] Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
    Herbst, Roy S.
    Soria, Jean-Charles
    Kowanetz, Marcin
    Fine, Gregg D.
    Hamid, Omid
    Gordon, Michael S.
    Sosman, Jeffery A.
    McDermott, David F.
    Powderly, John D.
    Gettinger, Scott N.
    Kohrt, Holbrook E. K.
    Horn, Leora
    Lawrence, Donald P.
    Rost, Sandra
    Leabman, Maya
    Xiao, Yuanyuan
    Mokatrin, Ahmad
    Koeppen, Hartmut
    Hegde, Priti S.
    Mellman, Ira
    Chen, Daniel S.
    Hodi, F. Stephen
    [J]. NATURE, 2014, 515 (7528) : 563 - +